Ann: Cultivation Licence Granted by the Office of Drug Control, page-52

I agree with all of that ... BUT this management has a few hard lessons to learn to grow out of GEN-Y "status", one of which, only one of which, is that you cannot sit there and expect instant gratification a few days before the options are due to expire. They need to learn communicating substance is the key to success.

I think they have been learning these lessons ("social media" thread stopping - fingers crossed - is a good sign) and hopefully with some revenue and a bit of luck, we may have the options exercised, otherwise, yes it will be tough BUT hopefully this management growing out of GEN-Y into maturity will be a valuable asset to hopefully help after this. This stock being seen as a "pot" stock by the pubic critically needs a management that is mature and professional to change the image, specially if we are going to penetrate the medical market, as we are.